Isaac Barchas Sells 100,000 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 100,000 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $22.59, for a total value of $2,259,000.00. Following the transaction, the director directly owned 208,504 shares in the company, valued at approximately $4,710,105.36. This represents a 32.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total value of $2,134,176.00.

Immunome Stock Performance

Shares of IMNM stock opened at $23.61 on Friday. The stock has a 50 day moving average price of $20.96 and a 200 day moving average price of $21.80. Immunome, Inc. has a 52-week low of $7.96 and a 52-week high of $27.65. The firm has a market capitalization of $2.67 billion, a P/E ratio of -9.92 and a beta of 2.07.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.12. As a group, sell-side analysts forecast that Immunome, Inc. will post -2.06 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Truist Financial upped their price target on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Wedbush reiterated an “outperform” rating and set a $31.00 price objective on shares of Immunome in a report on Friday, June 12th. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Immunome in a research report on Wednesday, May 13th. Finally, Leerink Partners dropped their target price on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research note on Friday, May 15th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.17.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in IMNM. Creative Planning lifted its position in shares of Immunome by 4.0% in the 3rd quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after purchasing an additional 710 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of Immunome by 14.4% during the fourth quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock valued at $159,000 after purchasing an additional 935 shares in the last quarter. California State Teachers Retirement System increased its holdings in Immunome by 1.8% during the fourth quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock valued at $1,439,000 after buying an additional 1,167 shares during the period. Assetmark Inc. increased its holdings in Immunome by 46.6% during the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after buying an additional 1,442 shares during the period. Finally, Virtus Investment Advisers LLC increased its holdings in Immunome by 16.9% during the fourth quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock valued at $292,000 after buying an additional 1,970 shares during the period. Hedge funds and other institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.